



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

[Handwritten signature]

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/001,938	10/31/2001	Salvatore Albani	UCSD1360-1	8878
7590	12/14/2005		EXAMINER	
LISA A. HAILE PH.D. GRAY CARY WARE & FREIDENRICH LLP 4365 EXECTIVE DRIVE SUITE 1100 SAN DIEGO, CA 92121-2133			SZPERKA, MICHAEL EDWARD	
			ART UNIT	PAPER NUMBER
			1644	
DATE MAILED: 12/14/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/001,938	ALBANI ET AL.	
	Examiner Michael Szperka	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 29 September 2005.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 57-59, 62-66 and 74 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 57-59, 62-66 and 74 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection on September 29, 2005. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 20, 2005 has been entered.

Applicant's reply and amendment to the claims received June 20, 2005 is acknowledged and has been entered.

Claims 57 and 74 have been amended.

Claims 57-59, 62-66, and 74 are currently pending.

Applicant's amendments to the claims received June 20, 2005 are sufficient to overcome all outstanding rejections of record. The prior art search has been extended beyond the elected species of SEQ ID NO:3 since the peptide consisting of SEQ ID NO:3 appears to be free of the prior art.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Art Unit: 1644

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 57-59, 62, 66, and 74 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurzik-Dumke (WO 98/32772, see entire document).

Kurzik-Dumke discloses the peptide consisting of SEQ ID NO:19 of the instant specification and its use in immunizing animals to obtain polyclonal antibodies (see entire document, particularly the abstract). The peptide is taught as being linked to the carrier protein hemocyanin to form a chimeric polypeptide that is present in a pharmaceutical composition comprising sodium chloride and Freund's adjuvant (see particularly example 1, from line 25 of page 4 to line 13 of page 5).

Therefore, the prior art anticipates the claimed invention.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 57, 59, and 62-65 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurzik-Dumke (WO 98/32772, see entire document) in view of Pillai et al. (US Patent No. 5,334,379, see entire document).

The teachings of Kurzik-Dumke have been discussed above. These teachings differ from the instant claimed invention in that Kurzik-Dumke does not teach the use of cytokines as immunoadjuvants in her pharmaceutical compositions.

Pillai et al. teach compositions comprising cytokines as immunoadjuvants (see entire document, particularly the abstract). Cytokines taught for use include both pro- and anti-inflammatory cytokines (see particularly from line 10 of column 1 to line 45 of column 2). The use of cytokines offers numerous advantages, including the ability to induce a high titer antibody response using a smaller dosage of vaccine (see particularly lines 30-51 of column 6).

Therefore, a person of ordinary skill in the art would have been motivated to modify the pharmaceutical compositions taught by Kurzik-Dumke to include cytokines to gain the advantages of a high titer antibody response when using a smaller dosage of vaccine as taught by Pillai et al.

6. No claims are allowable.

Note that amending the claims such that they read only on the peptide consisting of SEQ ID NO:3 would appear to be allowable subject matter.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Szperka, Ph.D.
Patent Examiner
Technology Center 1600
November 29, 2005

Pat J. Nolan
Patrick J. Nolan, Ph.D.
Primary Examiner
Technology Center 1600
12/7/05